文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Are Benign and Borderline Brain Tumors Underreported?

作者信息

Li Xiang-Rong, Kruchko Carol, Wu Xiao-Cheng, Hsieh Mei-Chin, Andrews Patricia A, Huang Bin, Qiao Baozhen, Wohler Brad

出版信息

J Registry Manag. 2016 Winter;43(4):187-94.


DOI:
PMID:29595921
Abstract

BACKGROUND: Primary benign and borderline (BB) brain tumors have been reportable since 2004 by population-based cancer registries in the United States. Because these tumors often are diagnosed clinically at nonhospital settings, underreporting is a big concern. Despite this, the magnitude and geographic variations in underreporting are unknown. The objectives of this study are to assess variations in BB brain tumor incidence rate by registry and trend in comparison to malignant brain tumors, as well as to identify the factors associated with the completeness of BB brain tumor reporting. METHODS: North American Association of Central Cancer Registries (NAACCR) Cancer in North America (CINA) Deluxe 1995–2012 Analytic File, which included data from 47 US population-based cancer registries, was used. Age-adjusted incidence rate and average annual percent change (APC) were calculated. Correlation coefficients were used to assess the relationships between incidence rates and clinical factors. RESULTS: The overall age-adjusted incidence rate was 14.2 per 100,000 for BB brain tumors and 6.6 per 100,000 for malignant brain tumors. The age-adjusted incidence rates of BB brain tumors varied by registry from 9.8 per 100,000 to 19.9 per 100,000, whereas the variations in malignant brain tumors were much smaller from 4.1 per 100,000 to 7.7 per 100,000. BB brain tumor cases were more likely than malignant brain tumors to be diagnosed through radiography without microscopic confirmation or surgery. Overall, the BB brain tumor incidence rate significantly increased by 2.3% per year from 2004 to 2012. In contrast, incidence rates of malignant brain tumors significantly decreased by 0.9% per year in the same period. Higher BB brain tumor incidence rates were significantly associated with higher proportions of cases without microscopic confirmation or surgery. These associations were not observed for malignant brain tumors. CONCLUSIONS: Incidence rates of BB brain tumors varied substantially across 47 US registries and were higher than those of malignant brain tumors in the United States. The variations in incidence rate of BB brain tumors may be largely attributable to difference in identifying clinically diagnosed cases. The increasing incidence rate of BB brain tumors may reflect improved case ascertainment rather than a biological trend. Key words:

摘要

相似文献

[1]
Are Benign and Borderline Brain Tumors Underreported?

J Registry Manag. 2016

[2]
The Central Brain Tumor Registry of the United States Histopathological Grouping Scheme Provides Clinically Relevant Brain and Other Central Nervous System Categories for Cancer Registry Data.

J Registry Manag. 2022

[3]
Italian cancer figures, report 2012: Cancer in children and adolescents.

Epidemiol Prev. 2013

[4]
Primary brain tumor incidence rates in four United States regions, 1985-1989: a pilot study.

Neuroepidemiology. 1996

[5]
The Impact of Hospital Discharge Linkage on Case Ascertainment of Brain Tumors in the Alberta Cancer Registry, 2010-2015.

J Registry Manag. 2018

[6]
Descriptive epidemiology of pituitary tumors in the United States, 2004-2009.

J Neurosurg. 2014-9

[7]
Epidemiology of meningiomas post-Public Law 107-206: The Benign Brain Tumor Cancer Registries Amendment Act.

Cancer. 2015-7-15

[8]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021.

Neuro Oncol. 2024-10-6

[9]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Neuro Oncol. 2019-11-1

[10]
CBTRUS Statistical Report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.

Neuro Oncol. 2024-5-6

引用本文的文献

[1]
Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Mol Cancer. 2025-2-26

[2]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.

Neuro Oncol. 2023-10-4

[3]
Signaling pathways in brain tumors and therapeutic interventions.

Signal Transduct Target Ther. 2023-1-4

[4]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.

Neuro Oncol. 2022-10-5

[5]
Pediatric Cancer By Race, Ethnicity and Region in the United States.

Cancer Epidemiol Biomarkers Prev. 2022-10-4

[6]
Preoperative Stereotactic Radiosurgery for Glioblastoma.

Biology (Basel). 2022-1-26

[7]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.

Neuro Oncol. 2021-10-5

[8]
Incidence of Benign Meningiomas in the United States: Current and Future Trends.

JNCI Cancer Spectr. 2021-6

[9]
Nonmalignant meningioma and vestibular schwannoma incidence trends in the United States, 2004-2017.

Cancer. 2021-10-1

[10]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.

Neuro Oncol. 2020-10-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索